Physician profile
Smita Ojha
NPI 1922184498
$2,076.13
in general payments reported to CMS, 2019-2025
12 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.79 · 2021: $268 · 2022: $742 · 2023: $238 · 2024: $508 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $372.60 | 2022-2025 | Freestyle Libre 3, Infinity |
| Novo Nordisk INC | $364.49 | 2021-2025 | Wegovy, Ozempic |
| Horizon Therapeutics Plc | $206.79 | 2019-2022 | |
| Medtronic, INC. | $176.32 | 2021-2022 | |
| Edwards Lifesciences Corporation | $153.50 | 2024 | Sapien 3 Ultra Resilia |
| Grt US Holding, INC. | $125.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.88 | 2022 | |
| Amgen INC. | $119.99 | 2024 | Evenity |
| Averitas Pharma INC. | $119.24 | 2024 | Qutenza |
| Radius Health, INC. | $115.00 | 2024 | Tymlos |
| Xeris Pharmaceuticals, INC. | $101.27 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smita Ojha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.